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Age-related macular degeneration (AMD), a leading cause of blindness in the United States, is a
neovascular disease that may be controlled with radiation therapy. Early patient outcomes of
external beam radiotherapy, however, have been mixed. Recently, a novel multimodality treatment
was developed, comprising external beam radiotherapy and concomitant treatment with a vascular
endothelial growth factor inhibitor. The radiotherapy arm is performed by stereotactic
radiosurgery, delivering a 16 Gy dose in the macula (clinical target volume, CTV) using three
external low-energy x-ray fields while adequately sparing normal tissues. The purpose of our
study was to test the sensitivity of the delivery of the prescribed dose in the CTV using this
technique and of the adequate sparing of normal tissues to all plausible variations in the position
and gaze angle of the eye. Using Monte Carlo simulations of a 16 Gy treatment, we varied the
gaze angle by ±5° in the polar and azimuthal directions, the linear displacement of the eye ±1 mm
in all orthogonal directions, and observed the union of the three fields on the posterior wall of
spheres concentric with the eye that had diameters between 20 and 28 mm. In all cases, the dose in
the CTV fluctuated <6%, the maximum dose in the sclera was <20 Gy, the dose in the optic disc,
optic nerve, lens and cornea were <0.7 Gy and the three-field junction was adequately preserved.
The results of this study provide strong evidence that for plausible variations in the position of the
eye during treatment, either by the setup error or intrafraction motion, the prescribed dose will be
delivered to the CTV and the dose in structures at risk will be kept far below tolerance doses.
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1. Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in
those older than 50 in developed countries (Jager et al 2008). In 2000, 8.5 million people in
the United States (14% prevalence) 55 years of age and older had intermediate or advanced
AMD (Bressler et al 2003). There are two forms of AMD, dry and wet. In the dry form,
vision deteriorates slowly and deposits known as drusen accumulate on the retina. No
treatment has been approved by the Food and Drug Administration for dry AMD, though
nutritional intervention may be effective (AREDS 2001). The wet form, on the other hand, is
characterized by the rapid growth of capillaries in the retina that leak blood and fluid,
causing scarring and damage to retinal cells. Frequently centered on the fovea, this
neovascularization can result in rapid and permanent loss of central vision. Although there is
currently no cure, wet AMD is commonly treated with an injection of a vascular endothelial
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growth factor (VEGF) inhibitor such as ranibizumab into the eye. Injection of VEGF
inhibitors has been shown to decrease both neovascularization and fluid accumulation in the
retina, and vision can be improved and maintained (Rosenfeld et al 2006a, 2006b).
However, while the results have been promising, the injections are costly and invasive and
must be repeated regularly to arrest deterioration of vision (Brown et al 2008).

NIH-PA Author Manuscript

As wet AMD is a neovascular disease, it is responsive to radiation therapy. The positive
effects of radiation are likely due to the inhibition of rapidly growing vascular endothelial
cells, disruption of cytokines and reduction of the inflammatory response (Finger et al
1998). Patient outcomes after external beam radiotherapy have been mixed for both photon
radiotherapy (Avila et al 2009b) and proton radiotherapy (Moyers et al 1999, Yonemoto et
al 2000, Zambarakji et al 2006). Moyers et al reported on the potential improvement on
sparing of normal tissues by using narrow proton beams instead of photon beams. More
consistently favorable results have been obtained with high-dose-rate brachytherapy, which
is given in highly localized single, large fractions (Jaakkola et al 2005). A technique
involving a single epiretinal application of a strontium-90 source directly to the fovea has
been particularly effective (Avila et al 2009a). In addition to maintaining or improving
patient vision, it has shown a dramatic reduction (or elimination) in the need for anti-VEGF
injections. This technique has been applied with and without VEGF inhibitors. However, the
strontium-90 source is placed onto the choroidal neovascularization via core vitrectomy,
which can have adverse effects.
Recently, an external beam treatment has been developed by Oraya Therapeutics, Inc.
(Newark, CA) that delivers a radiosurgical dose in the macula (i.e. clinical target volume,
CTV) using narrow, low-energy (superficial at 100 kVp) x-ray fields that largely spare the
optic disc, optic nerve, cornea, lens and brain and keep the maximum dose in the sclera well
below tolerance doses. This novel radiation treatment technique is particularly convenient
for the patient, as it is non-invasive, involves no sedation, and requires only a single sitting.
Previous studies have characterized the radiation fields (Lee et al 2008) used and the
radiation safety of the patients during the procedure (Hanlon et al 2009). However, to date,
the dosimetric impact of variations in the position and orientation of the eye during
treatment is not known.
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The purpose of this study was to investigate the sensitivity of the absorbed dose in the CTV
and the structures at risk (SARs) to plausible variations in the gaze angle and linear
displacement of the eye during treatment. Using Monte Carlo simulations of a 16 Gy threefield treatment, we calculated the absorbed dose in the CTV and the SARs while varying the
gaze angles and displacement of the eye. For all types of setup error and intrafraction
motion, we found that the prescribed dose in the CTV was stable and the SARs were
adequately spared.

2. Materials and methods
2.1. Treatment technique
In the treatment position, the patient is seated in front of the stereotactic radiosurgery system
(IRay™, Oraya Therapeutics, Inc.), as shown in figure 1. The patient places his or her chin
on the chinrest, and the headholder is lowered over the back of the patient’s head to firmly
hold the patient’s forehead against a padded bar, lightly immobilizing the head. With the
head stabilized, the lid is retracted using a customized lid retractor and the eye is gently
immobilized using a suction-cup-like fixture (I-Guide™, Oraya Therapeutics, Inc.), as
shown in figure 2. The fixture consists of a suction-enabled contact lens attached to a center
post that rotates via a ball joint in a horizontal stabilizer bar that is mounted to the
headholder. After the lens is centered on the patient’s limbus, suction is applied to affix the
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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fixture to the eye. This stabilizes the eye and causes the center post of the fixture to be
coaxial with the geometric axis of the eye. The geometric axis of the eye defines the
spherical treatment coordinate system, with the posterior pole defined as the intersection of
the geometric axis (or ‘z-axis’) with the retina. The fovea is offset approximately 1.2 mm
temporally and 0.5 mm inferiorly from the posterior pole. The radiosurgery system uses the
positions of three retro-reflective fiducials mounted on the fixture to correctly position itself
relative to the eye’s geometric axis and deliver the treatment beams to the macula.
The radiosurgery system has a custom two-camera video imaging and tracking system that
continuously monitors the positions of the fixture fiducials. For the initial alignment, the two
fiducials on the stabilizer bar are used to bring the x-ray source into treatment position; the
system has a mechanical targeting precision of approximately 200 μm. During treatment, the
relative positions of all three fiducials are monitored in real time to calculate the gaze angle
of the eye, the position of the eye relative to the starting position and the effective position
of the treatment beam on the retina. Although the head and eye are immobilized, for patient
comfort they are not rigidly fixed. However, computer software monitors the position of the
beam on the retina and gates off the beam in the event of excess motion of the eye, for
example if the patient’s gaze drifts or head moves (see sections 2.4–2.6).
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A prescribed absorbed dose of 16 Gy is delivered to a 4 mm diameter disc, which is the
CTV, centered on the fovea. Three narrow beams overlap at the fovea to reduce the entrance
dose in the pars plana, as shown in figure 3. The radiosurgery system is constrained to
deliver beams along the surface of a cone with the vertex 150 mm from the anode (sourceto-axis distance), regardless of the size of the patient’s eye. The cone angle is variable, from
20° to 30°, and the fovea is positioned at the vertex of the cone. The beams are 4 mm in
diameter (90% isodose) at the location of the fovea. Each beam enters the globe through
three distinct positions on the pars plana, at azimuthal angles of 150°, 180° and 210°, and
converges on the CTV. These field orientations were selected so that the beams would avoid
the lens, cornea and optic nerve (Lee et al 2008) and the x-ray source could be positioned
close to the eye while still providing adequate clearance with the patient’s brow, cheek and
eye lids. The radiosurgery system includes an x-ray tube (MXR160HP/11, Comet AG,
Flamatt, Switzerland) operating at 100 kVp, 18 mA and 1.8 kW. The only patient-specific
parameter of the treatment is the axial length of the eye. This affects targeting, as indicated
by the distance that the radiosurgery system should be from the fixture fiducials, and
treatment time (i.e. the length of tissue traversed by the beam is proportional to the axial
length, so it directly affects the beam-on time). A 16 Gy treatment requires less than 5 min
of irradiation time; the total treatment time, including setup, delivery and release of the
patient, takes approximately 20 min.
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2.2. Monte Carlo model
Monte Carlo simulations were performed using the Monte Carlo N-Particle eXtended
(MCNPX) code, version 2.6b (Pelowitz 2008). The MCNPX and MCNP codes are
commonly used in medical applications, including ocular radiotherapy using low-energy xray fields (Rivard et al 2006, Lee et al 2008, Hanlon et al 2009, Rivard 2009) and proton
beams (Herault et al 2005, Koch and Newhauser 2005, 2010, Mourtada et al 2005,
Newhauser et al 2007, Koch et al 2008). The geometric model (figure 4) comprised an x-ray
source, a collimator assembly and an anthropomorphic eye protruding from a water tank.
The 100 kVp x-ray tube was simulated with the following components: a parallel beam of
100 keV electrons originating from a 1 × 1 mm2 rectangular source; a tungsten wedge
angled at 11°; a 0.8 mm thick beryllium window and a 19 mm thick brass housing, the
interior of which was evacuated. X-rays were produced by bombarding electrons on the
tungsten target. After exiting the beryllium window, the x-rays traveled through a collimator
assembly. Components of the collimator assembly in the field, from the farthest upstream
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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component to farthest downstream component, included a tungsten collimator, an aluminum
filter, a thin glass mirror (for a coaxial targeting laser) and a second tungsten collimator that
defined the field size. The thickness of the aluminum filter was 0.75 mm, the glass mirror
had a thickness of 0.15 mm and was at an angle of 45° (resulting in a thickness of 0.21 mm
along the beam axis), and the downstream collimator had an aperture with a 2.5 mm
diameter. The geometric model of the eye was created in the MCNPX code to replicate that
of Dobler and Bendl (2002) and was adapted from a model that was used in previous
investigations (Koch and Newhauser 2005, 2010, Koch et al 2008). For simplicity, the
material composition of the eye was liquid water. The axial length of the eye was 24 mm;
the center of the CTV was placed at the therapeutic target, which is 1.16 mm to the patient’s
right and 0.53 mm to the patient’s inferior from the intersection of the geometric axis of the
eye and the retina, commonly referred to as the posterior pole. The center of the eye was
shifted 7 mm from the edge of the water tank (i.e. the anterior surface of the eye extruded 5
mm out of the anterior surface of the water tank). The optic nerve was represented by a 3
mm diameter cylinder that extended 17.2 mm from the optic disc and was rotated 18.4° to
the patient’s left, with respect to the center of the eye. Thus, the eye model corresponded to
a patient’s right eye.
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Although the MCNPX code has been extensively used for low-energy photon simulations,
single-field simulations were also performed to verify the accuracy of the Monte Carlo
calculations against the measured data. In these simulations, the eye model and water tank
were replaced by a solid water phantom to be consistent with the apparatus used for the
measurements. The absorbed dose was calculated as a function of depth in adjacent,
cylindrical subvolumes along the central-beam axis (CMESH3 mesh tally in the MCNPX
code). The tally subvolumes were only within the phantom and were each 2 mm in height
and 2.5 mm in diameter. To characterize the field at the depth of the CTV, lateral dose
distributions were calculated in a two-dimensional matrix of 2 × 0.5 × 0.5 mm3 voxels, with
the 2 mm dimension along the central-beam axis, centered at a depth of 21.8 mm and
extending from −10 to 10 mm in both lateral directions (RMESH3 mesh tally in the
MCNPX code). Additionally, beam hardening was observed by calculating the photon
spectral fluence (f4 discrete tally in the MCNPX code) immediately outside the x-ray tube,
immediately distal to the collimator assembly and in the water phantom at the depth of the
CTV (21.8 mm).
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Corresponding measurements were also performed following the guidelines of the American
Association of Physicists in Medicine (AAPM) Task Group 61 on kilovoltage dosimetry
(Ma et al 2001). Measurements of the absolute absorbed dose in water were made using a
parallel-plate ionization chamber (type N34013, PTW, Freiburg, Germany) together with an
electrometer (Unidos E, PTW, Freiburg, Germany). Measurements of the relative absorbed
dose in water were made using radiochromic film (Gafchromic® EBT Dosimetry Film,
International Specialty Products, Wayne, NJ) in a certified, therapy-grade solid water
phantom (457-CTG, Gammex-RMI, Middleton, Wisconsin), resulting in profiles of the dose
versus depth as well as the dose versus lateral position.
Three-field Monte Carlo simulations were performed for the sensitivity tests (see sections
2.4–2.6). For the three-field simulations with the eye model depicted in figure 3(a), the x-ray
tube and collimator assembly were first rotated 28° inferiorly. Next, the x-ray tube and
collimator assembly were rotated 30°, 0° and −30° to simulate the 5-o’clock, 6-o’clock and
7-o’clock beam orientations, respectively. Each rotation of the x-ray tube and collimator
assembly was about the center of the CTV. Thus, the three fields entered through the pars
plana at azimuthal angles of 150°, 180° and 210°. Discrete tallies volumes to calculate the
absorbed dose in the CTV and the SARs were placed in subvolumes located in strategic
locations within these structures, as explained in section 2.4.

Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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The results of the Monte Carlo simulations were normalized as follows. In all simulations,
the output of the Monte Carlo code was reported in terms of the absorbed dose or spectral
fluence per source particle (i.e. source electron). In the single-field simulations, we
calculated the number of source electrons required to deliver a mean dose of 5.33 Gy to the
CTV as the inverse of the absorbed dose per source electron (direct output of the Monte
Carlo code). Likewise, in the three-field simulations, we separately calculated the number of
source electrons required to deliver a mean dose of 5.33 Gy to the CTV for each of the three
fields. Thus, we normalized the single-field results to 5.33 Gy in the CTV and the results of
each of the three-field simulations to 5.33 Gy in the CTV for each field. The total absorbed
dose in the CTV for the three-field treatment was 16 Gy.
2.3. Variance reduction
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Two techniques were used to reduce the Monte Carlo simulation time and, thus, reduce
uncertainty. First, for each of the four field orientations (three fields for the treatment setup
and one field for the calibration setup), a phase space file of photons was created at the
upstream face of the beryllium filter within the x-ray machine. That is, the trajectories and
energies of all the photons that crossed the upstream face of the beryllium filter were
recorded in a data file for use in subsequent simulations. For the simulation in which the
single calibration field was simulated to create a phase space, 1.5 × 1011 electrons and their
secondary photons were tracked (MODE P E in the MCNPX code); for each of the treatment
field simulations, to create phase spaces, 1.5 × 1010 electrons and their secondary photons
were tracked (MODE P E in the MCNPX code). These phase space files were recycled for
subsequent Monte Carlo simulations, increasing the computational efficiency of the Monte
Carlo modeling. Second, geometry splitting was implemented in the Monte Carlo code on
several surfaces throughout the model, including the upstream face of the beryllium filter.
Implementing the geometry splitting reduced the variance by more than a factor of 2. All of
the subsequent simulations tracked each photon (MODE P in the MCNPX code), beginning
at the upstream face of the beryllium filter, until the energy of the photon fell below 1 keV
(the default cutoff for photons in MCNPX). The uncertainties in the values of the absorbed
dose and spectral fluence were estimated considering only statistical uncertainties and with
the assumption that component uncertainties were uncorrelated. Statistical uncertainties in
the absorbed dose and spectral fluence values were based on the coefficients of variation
reported by the Monte Carlo code and are reported at the 68% confidence interval.
2.4. Sensitivity to gaze angle
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In the treatment position, the eye position is fixed so that the patient looks straight ahead and
the beams converge at the fovea. Because of the possibility of the patient’s gaze drifting
during treatment, we tested the sensitivity of the absorbed dose in the CTV and the SARs to
the variation in gaze angle in the polar (i.e. vertical) and azimuthal (i.e. horizontal)
directions. During treatment, although the eye is stabilized by the fixture (see section 2.1),
eye and head motion are still possible. Because of this, a gating system is in place to track
the position of the eye and gate off the beam if the eye moves excessively. The gating
algorithm is a function that is linear in time and quadratic in displacement in order to allow
brief excursions that are not dosimetrically significant (e.g. spasm caused by blink response)
while shutting off the beam when actual drift occurs. In practice, a maximum of a 5° error in
gaze angle is expected (based on a small set of patient data). The software algorithm that
governs the gating system treats targeting as a two-dimensional problem. Therefore, to
conservatively investigate the impact that this deviation in gaze angle has on dosimetric
coverage of the CTV and sparing of the SARs, we calculated the absorbed dose in the CTV
and the SARs for the nominal case (i.e. deviating 0° polar and 0° azimuthal) and for cases
where the gaze angle deviated by ±5° in the polar and azimuthal directions. In the Monte
Carlo code, the absorbed dose was calculated in sub-millimeter-diameter spherical
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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subvolumes (f6 discrete tallies in the MCNPX code) in several locations—in the centers of
the CTV, lens and cornea, and in the regions nearest to the treatment field in the optic disc,
sclera, lens and cornea. The mean absorbed dose in the entire optic nerve was also
calculated.
2.5. Sensitivity to linear displacement
Because of the possibility of setup error or intrafraction motion of the patient’s eye, we
tested the sensitivity of the absorbed dose in the CTV and the SARs for plausible excursions
from the nominal setup position caused by patient motion during irradiation. The built-in
gating system attempts to keep the average position of the beam on the retina within 400 μm
of the setup position. Therefore, as a conservative test, we calculated the absorbed dose in
the CTV and the SARs for orthogonal linear displacements of ±1 mm separately in each
orthogonal direction—right and left, inferior and superior, and posterior and anterior. The
same tally volumes that were used in the gaze angle sensitivity test were used in this
displacement sensitivity test. In addition to simple targeting error, this tests the effects of
displacement on non-convergence of beams; that is, the radiosurgery system treatment
vertex stays stationary while the patient moves under it. Excessive anterior or posterior
motion could put the fovea in a region where overlap of the beams is incomplete.
2.6. Sensitivity of the three-field junction to the anterior–posterior position
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Because of the variation of the position of the eye along the anterior–posterior axis, which is
defined as the geometric axis of the eye, we tested the sensitivity of the union or the
separation of the three fields to the anterior–posterior position of the eye. In particular, we
quantified the convergence of the three beams along the posterior wall of concentric
spherical shells with diameters from 20 to 28 mm, which in clinical practice conservatively
encompasses all plausible variations in the anterior–posterior position of the eye. Dose tally
volumes in the form of segments along concentric spherical shells (2° × 2° segments,
diameters = 20 mm, 22 mm, 24 mm, 26 mm, 28 mm) were implemented in the Monte Carlo
model such that for the nominal eye size, with a 24 mm diameter, the shell crossed through
the CTV, sclera and optic disc. A limitation of this technique is that the human eye is
elliptical and not spherical. However, this limitation was of little consequence in this
sensitivity test because the region of interest, i.e. the macular region, including the CTV and
optic disc, is nearly spherical.

3. Results
NIH-PA Author Manuscript

3.1. Verification of the Monte Carlo dose predictions and characterization of the field at the
depth of the CTV
The relative absorbed dose along the central-beam axis versus depth in a solid water
phantom is shown in figure 5 from the single-field Monte Carlo simulation and
measurement. The excellent agreement between the Monte Carlo predictions and the
measured data verified the accuracy of the relative dose calculations from the Monte Carlo
code. The brain tissue begins at a depth of approximately 40 mm. The relative dose
calculated by Monte Carlo at depths of 21.8 mm (i.e. at the CTV) and 40 mm (i.e. at the
brain) were 32% and 14% (not shown), respectively. Thus, for a field that deposits 5.33 Gy
at the CTV, the maximum dose in the portion of brain tissue nearest to the eye is no more
than 2.4 Gy (assuming no type B uncertainties). This is a conservative estimate because
bone separates the brain from the eye, and more attenuation would occur in bone than in
water. Figure 6 shows the lateral dose profiles in both the horizontal and vertical directions
at the depth of the CTV for the Monte Carlo simulations and the film measurements. These
dose profiles verified that the field widths in the horizontal and vertical directions were
about 4 mm for the simulated and the measured data. The penumbrae were similar for the
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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simulated and measured data, with the measured data having a slightly sharper penumbra.
The penumbra from the measured data was slightly sharper because the actual focal spot
was smaller in diameter (0.85 mm) than the nominal value in the technical specifications (1
mm), on which the electron source in the Monte Carlo simulations was based.
Photon spectral fluences calculated by the Monte Carlo simulations are shown in figure 7 at
three locations along the central-beam axis. The plot at the machine exit represents the 100
kVp photon spectral fluence that results from a 100 keV electron source impinging on the
tungsten wedge, followed by the photons traveling through the exit window of the x-ray
tube. At this location, the lowest energy bremsstrahlung photons have been largely removed
by the beryllium filter in the exit window and the slightly hardened characteristic x-ray peak
remained at 9.5 keV. After traveling through the two aluminum filters, a quartz-glass mirror
and two tungsten collimators, the characteristic x-ray peak was removed, and the photons
below about 30 keV were preferentially attenuated. Finally, at the fovea, after traveling
through 21.8 mm of water, the photons with energies below approximately 40 keV were
preferentially attenuated and photons with energies below 15 keV were completely
removed. The average energy of the hardened x-ray spectrum at the fovea was 48.8 keV.
3.2. Sensitivity to gaze angle
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Fluctuations in the absorbed dose in the CTV and the SARs versus plausible gaze angles are
shown in figure 8. The values of the mean and the maximum absorbed dose in the CTV and
the SARs for the nominal gaze angle are plotted along with those for polar and azimuthal
deviations. For all plausible angular deviations in the gaze of the eye during treatment, the
dose in the CTV was within 5% of that in the nominal case, the maximum dose in the sclera
was 19 Gy, the maximum dose in the optic disc was 0.6 Gy, the maximum dose in the lens
was 0.3 Gy, and the mean dose in other SARs was less than 0.3 Gy. Therefore, the deviation
in the gaze angle during treatment is of minimal dosimetric consequence and presents very
low radiological danger to the optic disc and optic nerve.
3.3. Sensitivity to linear displacement
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Fluctuations in the absorbed dose in the CTV and the SARs for plausible linear
displacements of the eye along with the nominal case are shown in figure 9. The values of
the mean and the maximum absorbed dose in the CTV and the SARs for the nominal
placement of the eye are plotted along with those for 1 mm displacements in the right, left,
inferior, superior, posterior and anterior directions. For plausible displacements in
orthogonal directions (±1 mm), the dose in the CTV was within 6% of that in the nominal
case, the maximum dose in the sclera was 19 Gy, the maximum dose in the optic disc was
0.6 Gy, the maximum dose in the lens was 0.3 Gy and the mean dose in other SARs was less
than 0.3 Gy. Therefore, the motion of the patient along the geometric axes of the eye is of
minimal dosimetric consequence and presents very low radiological danger to the optic disc
and optic nerve within the variations stated herein.
3.4. Sensitivity of the convergence of the three fields to the anterior–posterior position
Figure 10 shows the plane projections of the spherical tally results, representing the union of
the three beams at several anterior–posterior positions. Conservatively, the uncertainty of the
position of the eye in the anterior–posterior direction is less than 1 mm. Therefore, spherical
shells with diameters of 22 mm, 24 mm and 26 mm (figures 10(c)–(e)) represent plausible,
realistic cases and spherical shells with diameters of 20 mm and 28 mm represent unrealistic
cases. In the realistic cases, the union of the three fields was preserved, adequate coverage of
16 Gy to the CTV was observed and the optic disc and optic nerve were adequately spared.
The spreading of the three beams at the largest concentric sphere, 28 mm diameter, (figure
10(f)) provides strong evidence that the fields completely separate before reaching the brain.
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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These results indicate that the coverage of the prescribed dose in the CTV and the sparing of
normal structures are not sensitive to plausible variations in the anterior–posterior position
of the eye.
3.5. Statistics and computing
The statistical uncertainties in the single-beam benchmarking results were less than 1%, and
the statistical uncertainties in the three-beam sensitivity testing results were less than 5%.
According to AAPM Task Group 61, ‘the final uncertainty in the absorbed dose…should be
better than ±5%’ (Ma et al 2001). The uncertainties in the absorbed dose values in this study
were within that of the AAPM protocol, and they were sufficient for demonstrating that no
significant difference was observed in the dose in the CTV for all types of setup error and
intrafraction motion.
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The simulations that resulted in phase spaces required a total of 6.5 days of computing time
with parallel processing on 500 2.6 GHz, 64-bit microprocessors (Opteron; Advanced Micro
Devices, Inc., Sunnyvale, CA); the final simulations that were based on the phase spaces
required a total of 2.2 days of computing time on a single 2.4 GHz microprocessor. For the
nominal single-field case, the number of source electrons required to deliver 5.33 Gy to the
CTV was 6.12 × 1018. For the nominal three-field simulations, the numbers of source
electrons required to deliver 5.33 Gy to the CTV were 6.7 × 1018, 7.0 × 1018 and 6.6 × 1018,
for the 5-o’clock, 6-o’clock and 7-o’clock beam orientations, respectively.

4. Discussion
The objective of this study was to test the sensitivity of a three-field stereotactic external
beam radiosurgery treatment for AMD to plausible variations in the gaze angle and position
of the eye caused by setup errors or motion during treatment. Specifically, using Monte
Carlo calculations, we quantified the dosimetric impact in the CTV and the SARs for
plausible variations in gaze angles and linear displacements. The results of this study
revealed that for all setup error and intrafraction motion of the eye the average absorbed
dose in the CTV remained stable (i.e. within 6% of the nominal dose) and covered the CTV
and the absorbed doses in the SARs (i.e. sclera, optic disc, optic nerve, lens, cornea, and
brain) were kept below acceptable limits. The Monte Carlo model and its predictions were
validated in terms of the relative dose against measurements.
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The treatment system includes a safety gating algorithm that terminates the beam in the
event that the calculated beam position on the retina deviates moderately from the nominal
position. However, the tolerance defining ‘moderate’ positional deviation was previously
somewhat simplistic, i.e. it ignored the effects caused by the separation of the fields in threedimensional space that may occur. This work has shown that the dosimetric effects of the
spreading of the fields are negligible in the CTV and that adequate treatment is maintained
for plausible variations in eye position examined.
The clinical implication of this study is that the dosimetric coverage provided by this
treatment technique is insensitive to the setup error and the intrafraction motion that is
typical for this treatment. This study supports the feasibility of escalating the dose in the
CTV, e.g. through hypofractionation, while sparing normal structures near and within the
eye. Although the dose in the sclera was up to 19 Gy, the sclera is radioresistant, and a dose
of less than 20 Gy does not result in any significant morbidity. Indeed, experience with
ocular melanomas has shown the absence of clinical effects at doses into the hundreds of Gy
(Missotten et al 1998, Hermann et al 2002, van Ginderdeuren et al 2005). We also found
that for realistic motion in the anterior–posterior direction, the displacement of the fovea
would have minimal impact on the overlap of the beam and would not pose a threat to the
Phys Med Biol. Author manuscript; available in PMC 2010 December 13.
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optic disc. Furthermore, because of the geometric orientation of the fields, the beams begin
to separate soon after the fovea and divide completely before encountering any critical
structures, e.g., the brain. A primary intention of using three fields rather than one was to
reduce the maximum doses to the brain and the sclera. The predicted brain dose in a singlefield simulation was less than 2.4 Gy (conservatively), and the findings of a previous study
that demonstrated that the mean dose in the brain was kept below 10 mGy for a 16 Gy
treatment (Hanlon et al 2009) provide strong evidence that hot spots greater than 3 Gy will
not occur in the brain. Together, these findings further support the use of this technique in a
clinical setting.
Previous attempts to use external photon radiotherapy for AMD have predominantly
involved MV beams with much larger fields (≫1 cm2) to assure adequate targeting. As
such, they have tended to include the entire optic nerve of the ipsilateral eye and,
occasionally, even the contralateral eye (Marcus et al 2001). In addition, the dose falloff in
tissue was gradual because of the high energy of the photons, resulting in higher doses in the
distal tissues than those of lower energy beams. Thus, the low energy of this radiosurgery
system is advantageous both because the beams attenuate rapidly before reaching the brain
and because secondary charged particles of lower energy beams travel a much shorter
distance than those of higher energy beams.

NIH-PA Author Manuscript

In conclusion, our study supports the feasibility of applying this adjuvant low-energy
external beam radiosurgical technique to patients with early- and late-stage AMD. For all
plausible setup errors and intrafraction motions of the eye, the delivered and prescribed
doses in the CTV agreed within 6% while keeping the dose in normal structures far below
tolerance dose levels. A European clinical trial is in progress, and a US pivotal trial is
foreseen.
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Figure 1.

Robotic stereotactic radiosurgery system. A test subject is shown with his head in the
treatment position within the immobilization system.
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Figure 2.
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(a) Eye stabilization and imaging fixture, (b) placed on a test subject’s eye. The suctionenabled contact lens is centered on the patient’s limbus, which establishes the geometric axis
of the eye as the treatment coordinate system. Three retro-reflective fiducials that are used to
determine the position and gaze angle of the eye in real time are shown; the central post is
free to rotate within the horizontal stabilizer bar that extends to the left-hand side in the
figure. The test subject’s lower eyelid is pulled completely out of the path of the fields using
a customized lid retractor.
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Figure 3.
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(a) Orientation of the three-field external beam treatment as the fields enter the eye
proximally through the pars plana and converge distally on the macula. (b) Fundus image of
a patient’s retina, with vasculature extending out of the optic disc and converging on the
macula (CTV), beneath a theoretical but typical dose wash showing a sharp penumbra of the
small, low-energy field. Black circles mark the optic disc and CTV, and the 90% and 10%
isodose lines are shown.
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Figure 4.
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Each component of the geometric model in the Monte Carlo simulations, including the x-ray
tube, collimator assembly and the eye in the mid-eye horizontal plane crossing through the
macula (CTV). Labeled in the diagram are the electron source, tungsten (W) wedge,
beryllium (Be) filter, water phantom, first tungsten collimator, aluminum (Al) filter, mirror,
aluminum holder, brass housing and second tungsten collimator. The subvolumes within the
eye are contoured in the zoomed-in diagram of the eye. In the eye, the shading represents the
energy deposited in angular segments in concentric spheres for the nominal 6-o’clock field
(log-scale, arbitrary units). The orientation of the x-ray tube/collimator assembly to the eye
and water phantom has been rotated out of the treatment position and into the X–Z plane for
this figure. The number scale on the left side of the figure represents distances from the focal
point in millimeters.
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Figure 5.

Percent depth dose in solid water along the central-beam axis for the single-field Monte
Carlo simulation (solid line) versus measurements (solid circles) made with film. Error bars
are contained within the line thickness and symbols, respectively.
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Figure 6.

Absorbed dose profiles through the isocenter (i.e. at the depth of the fovea) for the singlefield Monte Carlo simulation (solid line) versus measurements (solid circles) made with
film. The dose in voxels along the horizontal and vertical axes is shown in (a) and (b),
respectively. The data are normalized to deliver a mean of 5.33 Gy to the CTV. Error bars
are contained within the line thicknesses and symbols, respectively.
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Figure 7.

Photon spectral fluences for a single beam at three locations: at the exit of the x-ray tube,
after the filtration and collimation, and at the fovea, which is the center of the CTV. The
curves were first normalized to the delivery of 5.33 Gy to the CTV, and then the curves
other than the fovea curve were scaled for comparison, as shown in the legend. For clarity,
error bars are not shown; they are within three line widths in magnitude.
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Figure 8.

Fluctuations in the absorbed dose in the CTV and the SARs with respect to plausible
maxima in eye gaze angles during treatment. Angular values are shown for the eye gaze
deviating a combination of (polar, azimuthal) degrees. Values of the mean absorbed dose in
the structure are plotted, except where noted as the maximum absorbed dose in the structure.
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Figure 9.

Fluctuations of the absorbed dose in the CTV and the SARs with respect to plausible linear
displacement of the eye during treatment by ±1 mm in all orthogonal directions. The
nominal case, in which there was no displacement, is labeled as ‘none.’ Values of the mean
absorbed dose in the structure are plotted, except where noted as the maximum absorbed
dose in the structure.
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Figure 10.

Absorbed dose distributions in segments along the back of the eye for spheres with diameter
between 20 and 28 mm. The arrow represents the size and direction of the 6-o’clock field,
and the Z direction points from anterior to posterior, with the eye facing to the left of the
page. The diameters of the spherical-shell tally volumes are labeled along with the
approximate locations of the CTV and optic disc. The 24 mm diameter sphere (d) represents
the nominal case. The gray dot in each figure marks the location of the posterior pole of the
spherical tally.
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